Cardiovascular Health

Study shows rivaroxaban (Xarelto, Bayer) following nonmajor orthopedic surgery reduced the risk of major venous thromboembolism by approximately 75% compared with enoxaparin.

Patients with symptomatic peripheral artery disease who took rivaroxaban (Xarelto, Bayer) saw a 15% reduction in the risk of major adverse limb and cardiovascular events.

A recent study has detailed information on the potential dangers and the application of QTc monitoring to guide treatment when using drugs that can cause heart rhythm changes.

A prespecified exploratory analysis using the safety data from the 3 trials indicated fewer major adverse cardiovascular events (MACE) with inclisiran compared with placebo.

All 3 trials reached their primary endpoints, specifically percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to 17 months and time-adjusted percentage change in LDL-C from baseline from 3 to 18 months.

Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.

Staying on top of oral hygiene may be connected to a lower risk of atrial fibrillation and heart failure.

A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

Top news of the day from across the health care landscape.

Managing elevated cholesterol is one of the the key elements to decreasing negative outcomes in atherosclerotic cardiovascular disease.

A patient at age 65 with high blood pressure could extend their life by more than a year with intensive treatment focused on a target systolic blood pressure of less than 120 mm Hg.

The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.

Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.

Top news of the day from across the health care landscape.

An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.

cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.

Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.

The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.

Transthyretin amyloid cardiomyopathy is a rare and fatal disease for which there are no previously approved treatments.

Top news of the day from across the health care industry.

As a result of the agreement, Teva is licensed to launch a generic version of liraglutide (Victoza, Novo Nordisk) as of December 22, 2023.

Researchers at University of Texas Health Science Center at San Antonio studied 28,000 childhood cancer survivors to determine similarities in long-term effects for various chemotherapies.

The benefits of statin therapy for most people outweigh the risks.

During a recent panel discussion, 5 pharmacists and physicians raised key points about reducing the cost of managing nonvalvular atrial fibrillation (NVAF).

Janssen's Xarelto (rivaroxaban) is now indicated for reducing the risk of major cardiovascular events, such as death, myocardial infarction, and stroke, in people with chronic coronary or peripheral artery disease.

Daily aspirin did not reduce the occurrence of major cardiovascular events a study of more than 12,500 participants considered to be at risk, according to the results of the ARRIVE trial.

Serious vascular events in patients with diabetes can be prevented with aspirin use, according to results of the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial, which were presented at the ongoing ESC Congress in Munich, Germany.

Daily aspirin did not reduce the occurrence of major cardiovascular events a study of more than 12,500 participants considered to be at risk.

The benefits of taking aspirin to prevent a second or subsequent cardiovascular event have been well established in previous studies but the effectiveness of taking aspirin to prevent a first cardiovascular event has been unclear, despite 30 years of randomized clinical trials.

Top news of the day from across the health care landscape.